Results 111 to 120 of about 19,808 (220)

Radioligand therapies in cancer

open access: yes
We performed a systematic survey to assess the existing gaps in Europe in multidisciplinary education for integration of radioligand therapy (RLT) into cancer care and to obtain detailed information on the current limitations and key contents relevant.
Bugani, Valentina   +17 more
openaire   +1 more source

Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT

open access: yesScientific Reports
Candidates for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC) frequently have “mismatch” lesions with pronounced 18-fluorodeoxyglucose ([18F]FDG) but attenuated PSMA
Florian Rosar   +9 more
doaj   +1 more source

225Aс-PSMA-617 therapy in metastatic castration-resistant prostate cancer

open access: yesСибирский онкологический журнал
177Lu-PSMA-617 is a new therapy option for PSMA-positive metastatic castrate-resistant metastatic prostate cancer (mCRPC) with proven efficacy. 225Ac-PCMA-617 is an alpha emitter, making this drug potentially more powerful.
T. Yu. Kochetova   +3 more
doaj   +1 more source

High expression of peptide receptors as a novel target in gastrointestinal stromal tumours [PDF]

open access: yes, 2018
Recent significant advances in understanding the biology of gastrointestinal stromal tumours (GIST) have led to the introduction of a new targeted therapy (imatinib mesylate, Glivec).
Guillou, Louis   +4 more
core  

177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice

open access: yesCurrent Oncology
Prostate-specific membrane antigen (PSMA) is highly expressed in prostate cancer and a therapeutic target. Lutetium-177 (177Lu)-PSMA-617 is the first radioligand therapy to be approved in Canada for use in patients with metastatic castration-resistant ...
Kim N. Chi   +12 more
doaj   +1 more source

Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours [PDF]

open access: yes, 2018
Purpose: Radiolabelled somatostatin-based antagonists show a higher uptake in tumour-bearing mouse models than agonists of similar or even distinctly higher receptor affinity.
Borkowski, Sandra   +8 more
core  

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024

open access: yesCurrent Oncology
The Eastern Canadian Gastrointestinal Cancer Consensus Conference was an annual meeting that was held in St. John’s, Newfoundland and Labrador, from 26 to 28 September 2024. This included experts in medical oncology, radiation oncology, surgical oncology,
Jennifer Leigh   +34 more
doaj   +1 more source

Home - About - Disclaimer - Privacy